The best indicator for Cigna (CI)
We backtested 20 indicators across daily, weekly and hourly charts on real Cigna (CI) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Donchian Midline
On the weekly chart, this is the strongest risk-adjusted edge we found for Cigna (CI) over ~44.3 years — trailing buy-and-hold by 1.4% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Donchian Midline ✓ | Weekly | 10.2% | 0.56 | -48.4% | 43.4% | 106 | -1.4% |
| 2 | RSI Trend (>50) ✓ | Daily | 9.1% | 0.52 | -52.2% | 41.6% | 567 | -2.7% |
| 3 | Donchian Midline ✓ | Daily | 8.2% | 0.48 | -62.0% | 42.3% | 577 | -3.6% |
| 4 | MACD ✓ | Weekly | 8.2% | 0.48 | -57.4% | 53.3% | 92 | -3.5% |
| 5 | EMA-10 Trend ✓ | Weekly | 8.3% | 0.48 | -47.8% | 50.3% | 187 | -3.3% |
| 6 | EMA 50/200 Cross ✓ | Daily | 8.2% | 0.46 | -52.6% | 50.0% | 28 | -3.6% |
| 7 | EMA 20/50 Cross ✓ | Daily | 7.7% | 0.46 | -63.7% | 44.0% | 100 | -4.1% |
| 8 | EMA 20/50 Cross ✓ | Weekly | 8.1% | 0.46 | -52.7% | 55.0% | 20 | -3.6% |
| 9 | SMA 50/200 Cross ✓ | Daily | 8.0% | 0.45 | -52.8% | 53.1% | 32 | -3.8% |
| 10 | Rate of Change ✓ | Weekly | 7.7% | 0.45 | -62.8% | 50.0% | 140 | -3.9% |
| 11 | RSI Trend (>50) ✓ | Weekly | 6.9% | 0.43 | -46.4% | 47.1% | 119 | -4.7% |
| 12 | Bollinger Breakout ✓ | Weekly | 5.7% | 0.42 | -34.3% | 60.5% | 43 | -5.9% |
| 13 | EMA-10 Trend | Daily | 6.0% | 0.38 | -61.7% | 42.7% | 982 | -5.8% |
| 14 | Donchian Breakout ✓ | Weekly | 5.2% | 0.37 | -45.5% | 51.2% | 43 | -6.4% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Cigna (CI), Donchian Midline on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.